

A collage of black and white photographs showing various attendees at the LSX World Congress. The images depict people in professional settings, some speaking into microphones, others in discussion, and some holding documents. The collage is arranged in a grid-like fashion, with some images overlapping.

LSX | WORLD CONGRESS

STRATEGY, INVESTMENT, PARTNERING &
COMMERCIALISATION FOR LIFE SCIENCE
EXECUTIVE LEADERS

Wifi Network: etcvenues
Password: wifi8020

6th Annual

4-5 February, 2020
133 Houndsditch, Liverpool St
London, UK

#lsxworld @lsxleaders

Organised by:



The network
for life science
executive leaders

Final programme correct as of 03.02.2020

LSX World Congress

Welcome

STRATEGY, INVESTMENT AND PARTNERING FOR LIFE SCIENCE EXECUTIVE LEADERS

Welcome to the LSX World Congress 2020!

We're delighted to be returning for the 6th annual edition of Europe's leading executive strategy, partnering and investment congress. #LSXWorld 2020 is the biggest and best yet with 1,000 life science CXOs, investors, pharma heads and key stakeholders registered and more speakers, company showcases and partnering meetings than ever before!

Now encompassing the **Medtech Leaders** and three **Biotech Leaders** tracks - **Capital Markets & Investment**, **Partnerships & Deal Making** and **Capital Deployment & Commercialisation Strategy** as well as Inv€\$table and Lic€n\$able showcases, CEO and Pharma BD Leaders forums and workshops, the LSX World Congress is the all-encompassing strategy event that addresses all c-suite challenges and opportunities!

As always, we retain our relentless focus on quality peer-to-peer discussion, high-level networking and partnering, unique formats and a vetted, high-calibre audience to bring together the people that matter to the future of healthcare and life sciences.

The LSX World Congress Team

#LSXWorld
www.lsxleaders.com/lsx-world-congress
@LSXLeaders

Wifi: etcvenues
Password: wifi8020



Turbocharge your onsite experience

We've built a mobile app for LSX World Congress!

It has all the important information you'll need for the event and features to enhance your onsite experience.

There is a whole host of benefits to downloading the app:

- ✓ Personalise your onsite agenda
- ✓ Set notifications for sessions you're interested in
- ✓ Book 1:1 meetings

Step 1: Download the App!

If you haven't already, download the app on the device you have with you today.

Search for "LSX Events" or LSX Events in the App store for iOS phones, or Google Play store for Android phones.

Step 2: Log In

Open up the app once downloaded and login using your name and the email you used when registering for the conference.

Step 3: Verify

When prompted, enter the verification code sent to your email account (check all folders) and away you go. Any questions, please ask a member of the LSX Team.

Having problems with the App? Visit our information and help desk at the registration point and speak to Rebecca Herne, Operations Manager.

Our Partners

PLATINUM PARTNERS



GOLD PARTNERS



GOLD PARTNERS



SILVER PARTNERS



SUPPORTING PARTNERS



ROOM: ENTERPRISE 2

9:00 Welcome Address

Josh Dance, *SVP, LSX*

9:10 Keynote Panel: A sustainable connected European ecosystem: Building and strategically financing long-term sustainable Biotechs and life science clusters

Moderator: **Clive Cookson**, *Science Editor, Financial Times*
Onno van de Stolpe, *CEO, Galapagos*
Debbie Harland, *Partner, SR One*
Craig Johnstone, *COO, Evotec*
Geraldine O’Keeffe, *Partner Public Equities, LSP*
Sean Maret, *Chief Business and Chief Commercial Officer, BioNTech*
Tim Luker, *Sr. Director External Innovation, Lilly*

10:10 Keynote Presentation: Where’s the money going? Capital Markets Outlook

Ben Thorpe, *Head of Healthcare Banking EMEA, Goldman Sachs*

10:30 Morning Break

ROOM: ENTERPRISE 2

11:00 Capital Markets & Investment

11:00 Track Keynote Panel: New capital, syndication and capital alignment to build the European ecosystem

Moderator: **William Hicks**, *Co-chair of Securities & Capital Markets Practice Group, Mintz*
Tim Luker, *Sr. Director Ext. Innovation, Lilly*
Graziano Seghezzi, *Managing Partner, Sofinnova*
Sander Slootweg, *Managing Partner, Forbion Capital Partners*
Bibhash Mukhopadhyay, *Principal, New Enterprise Associates*
Sofia Ioannidou, *Partner, Andera Partners*

11:45 Fireside Chat: VC to DC - A new model for pension fund allocation to life science venture capital?

Moderator: **William Hicks**, *Co-chair of Securities & Capital Markets Practice Group, Mintz*
Alice Hu Wagner, *Managing Director, British Business Bank*

ROOM: SYNERGY 1

Partnerships & Deal Making

11:00 Track Keynote Panel: Building cross-industry and cross geography partnerships across Europe’s Biotech clusters and beyond

Moderator: **Robert Gebhardt**, *MD, PharmaVentures*
Jordi Naval, *CEO, Biocat*
Søren Bregenholt, *Chairman of the Board, Medicon Valley Alliance*
Michael Altorfer, *CEO, Swiss Biotech Association*
Annemiek Verkamman, *Managing Director, HollandBIO*

11:45 CEO Fireside Chat: Preparing EU Companies for international acquirers

Moderator: **Jonathan Gertler**, *Managing Partner & CEO, Back Bay Advisors*
Kate Bingham, *Managing Partner, SV Health Investors*

ROOM: ENGAGE

Capital Deployment & Commercialisation Strategy

11:00 Panel: Value-based pricing and advanced therapies

Moderator: **Thomas Lönngren**, *Former head of EMA, NDA*
Jason Ward, *Group Director, Innovation & Strategy, Oncology Market Access & Pricing, AstraZeneca*
Francis Pang, *VP Global Market Access, Orchard Therapeutics*
Mathias Flume, *Head of Department, KVWL*

11:50 Presentation: EMA Support to SMEs & Innovation

Constantinos Ziogas, *Head of SME Office, European Medicines Agency*

ROOM: INTERACT

9:00 Welcome Address

Kiron Campbell, *Conference Director, LSX*

9:05 Keynote Panel: M&A, consolidations, new value propositions, and commercial leadership in Medtech

Moderator: **Robbie McLaren**, *Partner, Latham & Watkins*
Charity Kufaas, *VP Strategy & Business Development EMEA, Medtronic*
Hani Abouhalka, *Company Group Chairman - Medical Devices EMEA, Johnson & Johnson*
Rupert Winckler, *Head of EMEA New Business Development, Olympus*

9:45 Keynote Panel: Unpacking value-based healthcare and multi-stakeholder led value creation

Moderator: **Stephen Dorrell**, *Chairman, Dorson and LaingBuisson*
Frank Maddux, *Global CMO, Fresenius Medical Care*
Maarten Akkerman, *Vice President Medical Affairs and Value-Based Healthcare, Medtronic*
John E Milad, *CEO, Quanta Dialysis*
Richard di Benedetto, *President and EVP, Aetna International*

ROOM: INTERACT

Medtech Leaders

11:00 Keynote Investment Panel: The peaks and troughs of the Healthtech investment landscape

Moderator: **Mark Andrews**, *Managing Director, Pharma Ventures*
Anat Naschitz, *Managing Director, Orbimed*
Martin Pfister, *Senior Investment Manager, High-Tech Gründerfonds*
Caroline Gaynor, *Vice President, Lightstone Ventures*
Alessio Beverina, *General Partner, Panakès Partners*
Arnd Kaltofen, *Partner, VI Partners*

11:40 Fireside Chat: IPO case study: Making a mark on Europe’s public markets

Moderator: **Tina Tan**, *Executive Editor, FirstWord Medtech*
Ian Crosbie, *CEO, Sequana Medical*

On Floor Showcases

Showcase opportunities exist in the 2020 congress for companies looking to raise finance (Inv€\$table) and/or attract interest in a licensing deal (Lic€n\$able).

These showcases are for all stages of private and public companies to present news and deal flow or pitch to an audience of active investors, pharma, Medtech commercial leaders and big tech.

Inv€\$table and Lic€n\$able are 15-minute showcase slots allowing companies to deliver succinct, hard-hitting and insightful presentations to an audience seeking to uncover innovative research and/or technology for capital and strategic transactions, and licensing and R&D collaborations.

Presenting company executives will present to a live audience, plus have their showcases video recorded and turned into a post-event strategic communications piece.

ROOM: ONFLOOR SHOWCASE AREA

11:00 Biotech Inv€\$table Showcase Medtech Inv€\$table Showcase Lic€n\$able Showcase

ROOM: SYNERGY 2

11:00 PUBLIC CEO FORUM

Co-hosted by

WHITE & CASE

This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

ROOM: INTEGRATE 3

11:00 PHARMA BD LEADERS FORUM

Co-hosted by





































This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

ROOM: BALCONY

11:00 INNOVATION ZONE

Co-hosted by

ROOM: ENTERPRISE 2		ROOM: SYNERGY 1		ROOM: ENGAGE		ROOM: INTERACT	
12:05	<p>Panel: Raising capital and diversity standards - addressing the imbalance</p> <p>Moderator: Lucie Ellis, <i>Managing Editor, In Vivo</i> Kyp Sirinakis, <i>Managing Partner, Epidarex Capital</i> Roel Bulthuis, <i>Managing Partner, Inkef</i> Rafaële Tordjman, <i>Founder & CEO, Jeito</i> Maina Bhaman, <i>Partner, Sofinnova</i> Fiona de Hemptinne, <i>Venture Partner, UCB Ventures</i></p>	12:05	<p>Panel: Passing the baton - Success in M&A deal-making</p> <p>Moderator: Gregory Benning, <i>Managing Director, Head of Investment Banking, Back Bay Life Science Advisors</i> Luc Dochez, <i>Co-founder, Pharvaris and former CEO, Tusk Therapeutics</i> Phil L'Hullier, <i>Head of BD, Europe, European Innovation Hub, MSD</i> Andy Staples, <i>Head of Deal Finance, AstraZeneca</i></p>	12:10	<p>Fireside Chat: Regulatory assistance for Europe's life science SMEs</p> <p>Moderator: Ben Howlett, <i>Director, World Healthcare Journal</i> Constantinos Ziogas, <i>Head of SME Office, European Medicines Agency</i></p>	12:05	<p>Panel: Attracting the big strategics; what CVC need to see</p> <p>Moderator: Elizabeth Cairns, <i>Reporter, Vantage</i> Jonathan Goldstein, <i>Director, Corporate Research and Ventures, Boston Scientific</i> Assaf Barnea, <i>CEO, Sanara Ventures</i> Jeanne Bolger, <i>VP Venture Investments, Johnson & Johnson Innovation</i> Andreas Wuepper, <i>Director Investments, Europe, Fresenius Medical Care Ventures</i></p>
12:45							
Lunch Break							
13:45	<p>Panel: Go big or go home? - evolving early investment strategies</p> <p>Moderator: Lisa Urquhart, <i>Editor, Vantage</i> Roger Franklin, <i>Partner, Hadean Ventures</i> Sara Secall, <i>Partner, INVEREADY</i> Montserrat Vendrell, <i>General Partner, Alta Life Sciences</i> Søren Lemonius, <i>Managing General Partner, Sunstone Life Science Ventures</i> Søren Møller, <i>Managing Partner, Novo Seeds</i></p>	13:45	<p>Panel: Positioning public partnerships - optimising deal-making when listed</p> <p>Moderator: Cody Powers, <i>Associate Principal, ZS</i> Renée Aguiar-Lucander, <i>CEO, Calliditas Therapeutics</i> Olav Hellebo, <i>CEO, ReNeuron</i> John Strafford, <i>VP, Head of BD, Silence Therapeutics</i> John Dawson, <i>CEO, Oxford BioMedica</i></p>	13:45	<p>Panel: Harnessing the drivers for success in your early stage programme</p> <p>Moderator: Carl Engleman, <i>Vice President, Cello Health Consulting</i> Caroline Barelle, <i>CEO, Elasmogen</i> Stuart Collinson, <i>CEO, Oxstem</i> Lars van der Veen, <i>COO, iOnctura</i></p>	13:45	<p>Panel: Commercial Success in Medtech through talent and team building</p> <p>Moderator: Kristien Esser, <i>CEO, Guided Solutions</i> Craig Marshall, <i>CEO, OrganOx</i> Christoph Ruedig, <i>Partner, Albion Capital</i> Simon Hubbert, <i>Chairman, Rhythm AI</i> Brian Howlett, <i>Non-Exec. Director, Accentus Medical</i> Angle, <i>Oxford Endovascular</i> Maina Bhaman, <i>Partner, Sofinnova</i></p>
14:25	<p>Fireside Chat: An A+ mega round launch</p> <p>Moderator: Lisa Urquhart, <i>Editor, Vantage</i> Mark Altmeyer, <i>CEO, Arvelle Therapeutics</i></p>	14:35	<p>Fireside Chat: Going with your gut in Pharma co-development</p> <p>Moderator: Lucie Ellis, <i>Managing Editor, In Vivo</i> Simon Baeriswyl, <i>COO, Enterome</i></p>	14:25	<p>Fireside Chat: Building A(I), and deploying A big B</p> <p>Moderator: John Hodgson, <i>Independent Consultant</i> Tim Guilliams, <i>CEO, Healx</i></p>	14:20	<p>Panel: Learnings and lessons from early-stage fundraising success stories</p> <p>Moderator: Todd Usen, <i>CEO, Activ Surgical</i> Mark-Jan Harte, <i>CEO, Aidence</i> Ian Wilson, <i>CEO, ImaginAb</i> Rainer Strohmenger, <i>Managing Partner, Wellington Partners</i> Ena Prosser, <i>Partner, FH Partners</i></p>
14:45	<p>Panel: Making the grade - B+ rounds and investor alignment</p> <p>Moderator: Jonathan Gertler, <i>Founder & CEO, Back Bay Life Science Advisors</i> Hakan Goker, <i>Executive Investment Director, M Ventures</i> Giovanni Mariggi, <i>Partner, Medixci</i> Jack Nielsen, <i>MD, Vivo Capital</i> Thibaut Roulon, <i>Investment Director - Life Sciences, Bpifrance</i> Clara Campàs, <i>Partner, Asabys Partners</i></p>	15:00	<p>Fireside Chat: Crafting win/win early-stage Biotech-to-Biotech partnerships</p> <p>Moderator: Lucie Ellis, <i>Managing Editor, In Vivo</i> Cedric Ververken, <i>CEO, Confo Therapeutics</i></p>	14:45	<p>Panel: Early planning and effective capital deployment when progressing through the clinic</p> <p>Moderator: John Hodgson, <i>Independent Consultant</i> Joe Dupere, <i>CEO, Rexgenero</i> Leon Hoofman, <i>CMO, ISA Pharmaceuticals</i> Grace E. Colón, <i>CEO, InCarda Therapeutics</i> Juho Jalkanen, <i>CDO, Faron Pharmaceuticals</i></p>	14:55	<p>Panel: Together we rise; tips and tricks for Healthtech partnerships</p> <p>Moderator: Roy Wiesner, <i>Managing Director, qMoon Fund</i> Brian Hakim, <i>Director of BD, MedTecX</i> Seamus Browne, <i>Head of Industry Partnerships, Royal College of Surgeons</i> Sascha Alilovic, <i>Partner, SHS Capital</i> John Power, <i>CEO, Aerogen</i></p>
15:30							
Afternoon Break							

ROOM: ONFLOOR SHOWCASE AREA			ROOM: SYNERGY 2		ROOM: INTEGRATE 3		ROOM: BALCONY	
<p>Biotech Inv€\$table Showcase</p> <p>Medtech Inv€\$table Showcase</p>			<p>PUBLIC CEO FORUM</p>		<p>PHARMA BD LEADERS FORUM</p>		<p>INNOVATION ZONE</p>	
12:15				<p>This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.</p>		<p>This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.</p>		
12:30								
12:45	<p>Lunch Break</p>							
13:45	<p>Biotech Inv€\$table Showcase</p>	<p>Medtech Inv€\$table Showcase</p>	<p>Cardio Metabolic</p>	13:45	<p>PRIVATE CEO FORUM</p>	<p>PHARMA BD LEADERS FORUM</p>	<p>INNOVATION ZONE</p>	
13:45				<p>Co-hosted by</p>	<p>Co-hosted by</p>	<p>Co-hosted by</p>		
14:00								
14:15								
14:30				<p>This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.</p>	<p>This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.</p>			
14:45								
15:00								
15:15								
15:30								
15:45								

ROOM: ENTERPRISE 2

16:00

Afternoon Keynote: Ad-vant-ages in building a Biotech family

Moderator: **Melanie Senior**, *Analyst and Specialist Writer*, Life Sciences
Matthew Gline, *CFO*, Roivant Sciences

16:20

Afternoon Keynote Panel: In conversation with pharma leaders - Innovation, efficiency and technology convergence

Moderator: **Ben Thorpe**, *Head of Healthcare Banking EMEA*, Goldman Sachs
Ivana Magovčević-Liebisch, *CBO*, Ipsen
Nigel Sheail, *Global Head of M&A and BD&L*, Novartis
Philippe Lopes-Fernandes, *SVP, Global Head of BD and Alliance Management*, Merck KGaA
Ben Thorner, *SVP, Global Business Development*, MSD

17:00

Closing Keynote Panel: R&D and the PRC - Regulatory reform, partnering and advancing development in China

Moderator: **Sam Fazeli**, *Head of European Research, Pharmaceuticals Analyst*, Bloomberg
Mirko Scherer, *CEO*, CoFeS China
Zishan Haroon, *Managing Partner*, Julz Co
Richard Yang, *Director of Pharmacovigilance Operations*, Fountain Medical Development
Guillaume Vignon, *SVP Business Development*, BeiGene
Donald Xu, *Managing Partner*, Lynx Financial

ROOM: EXHIBITION AREA

17:45

Networking Party

HOSTED BY:




18:30

Investor Dinner
If you have purchased a ticket to the Investor-only dinner, you will be directed from the conference venue at approx. 7pm to the dinner venue. Your badge will confirm you have a seat reserved. This dinner required pre-registration and is a sellout.

ROOM: ONFLOOR SHOWCASE AREA

16:00

Biotech Inv€\$table Showcase



Medtech Inv€\$table Showcase



Biotech Inv€\$table Showcase



16:00

ROOM: SYNERGY 2



Co-hosted by



This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.

ROOM: EXHIBITION AREA

17:45

Networking Party

HOSTED BY:



18:30

Investor Dinner
If you have purchased a ticket to the Investor-only dinner, you will be directed from the conference venue at approx. 7pm to the dinner venue. Your badge will confirm you have a seat reserved. This dinner required pre-registration and is a sellout.

ROOM: ENTERPRISE 2		ROOM: INTERACT	
9:25	Welcome Address Josh Dance, <i>SVP, LSX</i>	9:20	Welcome Address Kiron Campbell, <i>Conference Director, LSX</i>
9:35	Keynote Panel: The listing consideration - building on roots or the American dream? Moderator: Isabella Schidrich , <i>Managing Director, Nasdaq</i> Anthony Pagano , <i>SVP Finance and Corporate Development, Genmab</i> Kevin Lee , <i>CEO, Bicycle Therapeutics</i> Sean Marett , <i>Chief Business and Chief Commercial Officer, BioNTech</i> Christophe Douat , <i>CEO, MedinCell</i>	9:25	Keynote Panel: Building the IOMT ecosystem; connected devices, refined commercial strategies Moderator: Julie Bretland , <i>CEO, Our Mobile Health</i> Mathias Goyen , <i>Chief Medical Officer Europe, GE Healthcare</i> Patrik Sobocki , <i>Investment Manager, Industrifonden</i> Thomas Hummel , <i>Head of Innovation and Strategy, Siemens Healthineers</i> David Germonpré , <i>Partner, MTIP</i> Xavier Bertrand , <i>VP Healthcare Services and Alliances Emea, Boston Scientific</i>
		10:10	Keynote Fireside Chat: New frontiers - Taking Asian Medtech global Moderator: Summer Park , <i>Senior Business Development Director, PharmaVentures</i> Frank Yu , <i>CEO, Ally Bridge Group</i>
10:30	Morning Break		
ROOM: ENTERPRISE 2		ROOM: SYNERGY 1	
11:00	Capital Markets & Investment		
11:00	Track Keynote Panel: China's integration into global, the global pharma science and what this means for raising capital in Asia Karen Liu, <i>Partner, 3E BioVentures</i>	11:00	Partnerships & Deal Making Building a Biotech unicorn from scratch through partnerships Jens Hennecke, <i>Chief Business Officer, SOTIO/PPF Group</i>
11:20	Panel: New capital & growth - Asian investment into European life sciences Moderator: Ari Silverman , <i>Partner, Mavie Technologies</i> Katherine Cohen , <i>Venture Partner, Panacea Venture</i> Peter Bisgaard , <i>Managing Director, Nan Fung Life Sciences</i> Marietta Wu , <i>Managing Director, Quan Capital</i> Frank Yu , <i>CEO, Ally Bridge Group</i>	11:20	Panel: Are we there yet? Navigating the roadmap in early-stage partnerships Moderator: Adrian Dawkes , <i>Managing Director, PharmaVentures</i> Tomas Landh , <i>Innovation Sourcing Vice President, Senior Principal Scientist of Search and Evaluation, Novo Nordisk</i> Sergio Capancioni , <i>Director S&E Western Europe, AbbVie</i> Catherine Pickering , <i>CEO, iOnctura</i> Rick Davis , <i>Senior Director, New Ventures and Transactions, Oncology, Johnson & Johnson</i>
12:00	Fireside Chat: Mapping, supporting and financing European innovation and entrepreneurship Moderator: Mick Cooper , <i>Analyst, Trinity Delta</i> Adelaide Cracco , <i>Head of Life Sciences, European Investment Fund</i>		
		11:00	Capital Deployment & Commercialisation Strategy Panel: Going it alone - Challenges and late-stage capital deployment in self-commercialisation Moderator: Carl Engleman , <i>Vice President, Cello Health Consulting</i> Carl Sterritt , <i>CEO, Shield Therapeutics</i> Erik van den Berg , <i>CEO, AM-Pharma</i> Eduardo Bravo , <i>CEO, Nordic Nanovector</i> Kieran Rooney , <i>VP Strategic Alliances and Licensing, Amryt Pharma</i>
		11:00	Medtech Leaders Panel: Creating empowered, technologically enabled Healthtech consumers Moderator: Michael Branagan-Harris , <i>CEO, Device Access UK</i> Frances A. Ayalasomayajula , <i>Head of Population Health, HP</i> Richard di Benedetto , <i>President, Aetna</i> Steve Atkinson , <i>CEO, Atlantic Therapeutics</i> Ben Maruthappu , <i>CEO, Cera</i> Victoria Betton , <i>Founder, mHabitat, CIO, Mindwave Ventures</i>
		11:40	Fireside Chat: At the intersection of digitisation and value-based care Moderator: David Germonpré , <i>Partner, MTIP</i> Robbie Hughes , <i>CEO, Lumeon</i>
		12:00	Panel: Successfully navigating regulatory change; strategies responses to MDR and IVDR Moderator: Amanda Maxwell , <i>European Reg. Affairs Director, Medtech Insight</i> David Tuch , <i>CEO, Lightpoint Medical</i> Susana de Azevedo Wäsch , <i>VP Quality Management & Regulatory Affairs, Ypsomed AG</i> James Pink , <i>Senior Director, NSF International</i> Robert Abbott , <i>VP, Chief Legal Counsel EMEA, Stryker</i> Manuela Gazzard , <i>Group Executive Director Regulatory Services Healthcare, BSI Group</i>

On Floor Showcases

Showcase opportunities exist in the 2020 congress for companies looking to raise finance (Inv€\$table) and/or attract interest in a licensing deal (Lic€n\$able).

These showcases are for all stages of private and public companies to present news and deal flow or pitch to an audience of active investors, pharma, Medtech commercial leaders and big tech.

Inv€\$table and Lic€n\$able are 15-minute showcase slots allowing companies to deliver succinct, hard hitting and insightful presentations to an audience seeking to uncover innovative research and/or technology for capital and strategic transactions, and licensing and R&D collaborations.

Presenting company executives will present to a live audience, plus have their showcases video recorded and turned into a post-event strategic communications piece.






ROOM: ONFLOOR SHOWCASE AREA

11:00 **Biotech Inv€\$table Showcase**

- 11:00
- 11:15
- 11:30
- 11:45
- 12:00
- 12:15
- 12:30







Satellite Workshops

The workshops are intimate 90-minute interactive education forums in which CXOs are navigated through considerations, strategy and ideas for approaching key company milestones by an expert partner. The workshops run throughout day two of the World Congress covering M&A, clinical strategies, licensing & collaboration and market access.

ROOM: SYNERGY 2	ROOM: INTEGRATE 3	ROOM: BALCONY
		
Co-hosted by 	Co-hosted by 	Co-hosted by 
This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.	This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.	
Additional seats may be available on first-come first-served basis.	Additional seats may be available on first-come first-served basis.	

ROOM: ENTERPRISE 2		ROOM: SYNERGY 1		ROOM: ENGAGE		ROOM: INTERACT									
12:20	<p>Panel: PIPEs, pipelines and public equities</p> <p>Moderator: Mick Cooper, <i>Analyst, Trinity Delta</i> Mattias Häggblom, <i>Fund Manager, Swedbank Robur</i> Geraldine O’Keeffe, <i>Partner Public Equities, LSP</i> Ulrica Slåne Bjerke, <i>CIO, Arctic Aurora LifeScience</i> Marek Poszepczynski, <i>Portfolio Manager - International Biotechnology Trust, SV Health Investors</i></p>	12:10	<p>Panel: Platforms and partnerships</p> <p>Moderator: Andy Smith, <i>Analyst, Equity Development</i> Yochi Slonim, <i>CEO, Anima Biotech</i> Tim Luker, <i>Sr. Director External Innovation, Lilly</i> Jane Dancer, <i>CBO, F-Star</i> Giuseppe Mazza, <i>CEO, Engitix</i> Mike Romanos, <i>CEO, Microbiotica</i></p>	11:50	<p>Panel: The I in team - CEO strategy in C-Suite management & board development</p> <p>Moderator: Melanie Senior, <i>Analyst & Specialist Writer, Life Sciences</i> Don DeBethizy, <i>Director, Argenx and Chair to European biotechs</i> Sarah Shackleton, <i>Partner, Marketing & Talent, Abingworth</i> Edwin Moses, <i>former CEO, Ablynx</i> Denise Scots-Knight, <i>CEO, Mereo Biopharma</i> Annalisa Jenkins, <i>Chair to European biotechs</i></p>	12:40	<p>Fireside Chat: Fundraising and the real-world value in therapeutic AI</p> <p>Moderator: Bill Aronson, <i>COO, AI Research Group</i> Marc Julien, <i>Co-CEO, Diabeloop</i></p>								
13:00															
Lunch Break															
ROOM: ENTERPRISE 2				ROOM: INTERACT											
14:00	<p>Afternoon Keynote Panel: Health technology convergence - Driving the next wave of value in healthcare</p> <p>Moderator: Andy Smith, <i>Analyst, Equity Development</i> Anoop Maini, <i>CEO, Excite Ventures</i> Sumit Nagpal, <i>CEO and Co-Founder, CareFully</i> Junaid Bajwal, <i>Global Lead for Strategic Alliances, MSD</i></p>	14:00	<p>Growing opportunity, growing threat; cyber-security in the context of digitisation</p> <p>Moderator: Bill Aronson, <i>COO, AI Research Group</i> Leon Lerman, <i>CEO, Cynerio</i> Saif Abed, <i>Founding Partner, AbedGraham, Cyber Security Expert, European Commission and WHO</i> Jovan Stevovic, <i>CEO, Chino.io</i></p>	14:45	<p>Fireside Chat: Now and then - The true impact of AI on life sciences & realising AI potential</p> <p>Mark O’Herlihy, <i>Managing Director EMEA, IBM Watson Health</i></p>	14:40	<p>Panel: Healthtech’s reimbursement challenge in the digital age</p> <p>Moderator: Prof. Brian D Smith, <i>Principal Advisor, Pragmedic</i> Daniel O’Mahony, <i>Partner, Seroba Life Sciences</i> Luella Trickett, <i>Director Value and Access, Association of British HealthTech Industries</i> Rudy Dekeyser, <i>Managing Partner, LSP Health Economics Fund</i> Paul Brown, <i>CFO, NW London CCGs, NHS</i> Ali Hasan, <i>Chief Medical and Health Officer, Vitality</i></p>	15:10	<p>Closing Keynote Panel: Realising AI’s potential in life sciences and healthcare</p> <p>Moderator: John Hodgson, <i>Independent Consultant</i> Derk Arts, <i>CEO, Castor</i> Bharat Tewarie, <i>Former EVP & CMO, UCB</i> Alison Howie, <i>Chief Product Officer, IXICO</i> Parker Moss, <i>Board Member, CRUK</i></p>	15:30	<p>Closing Keynote Panel: Mapping Medtech’s future - New opportunities in collaboration and innovation</p> <p>Moderator: Prof. Brian D Smith, <i>Principal Advisor, Pragmedic</i> Fredrik Strömberg, <i>Senior Regional Director Northern Europe, Nobel Biocare</i> Edward Cox, <i>Digital Therapeutics CEO and Thought Leader , Dthera Sciences</i> Christoffer-Martin Seubert, <i>Lead for Strategic Alliances, Digital Health, Teamplay Platform, Siemens Healthineers</i> Richard Kivel, <i>Managing Director, GrayBella Capital</i> Julie Bretland, <i>CEO, Our Mobile Health</i></p>	16:00	<p>Close of Congress</p>	16:20	<p>Close of Congress</p>

Satellite Sessions

<p>PUBLIC CEO FORUM</p> <p>A Chatham House Rule, invite-only forum for CEOs, CFOs, CBOs and chairmen of listed life science and healthcare companies. The forum will feature peer-reviewed CEO and partner case studies, and an interactive general discussion.</p> <p>The Public CEO Forum is open only to life sciences companies listed on the public markets. This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.</p> <p>Co-Hosts:</p> <p> </p> <p>Timings:</p> <p>Feb 4, 11:00 - 12.45 - Synergy 2</p> <p>Case Studies</p> <p>Moderator: Philip Broke, <i>Partner, White & Case</i></p> <p>Case Study 1: ESG & Changes in Regulatory Environment</p> <p>Assaf Homossany, <i>MD-EMEA, Nasdaq</i></p> <p>Case Study 2: PIPEs deals and preparing for a US Listing</p> <p>Philip Broke, <i>Partner, White & Case</i></p> <p>Case Study 3: Gilead/Galapagos Alliance</p> <p>Onno Van de Stolpe, <i>CEO, Galapagos</i></p>	<p>PRIVATE CEO FORUM</p> <p>A Chatham House Rule, invite-only forum for CEOs, CFOs, CBOs and chairmen of private life science and healthcare companies. The forum will feature peer-reviewed c-level and partner case studies, and an interactive general discussion.</p> <p>The Private CEO Forum is only open to post series A private biotech companies. This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.</p> <p>Co-Hosts:</p> <p> </p> <p>Timings:</p> <p>Feb 4, 13:45 - 15.30 - Synergy 2</p> <p>Case Studies</p> <p>Moderator: Andrew Harrow, <i>Partner, Goodwin</i></p> <p>Case Study 1: Considerations and planning for going public in the US</p> <p>Assaf Homossany, <i>MD-EMEA, Nasdaq</i></p> <p>Case Study 2: Crossover Fundraising Strategies</p> <p>Sophie McGrath, <i>Partner, Goodwin</i></p> <p>Case Study 3: Successful US fundraising and IPOs</p> <p>Matt Gline, <i>CFO, Roivant</i></p>	<p>STARTUP CEO FORUM</p> <p>A Chatham House Rule, invite-only forum for CEOs of life science and healthcare startups.</p> <p>The forum will feature peer-reviewed c-level and partner case studies, and an interactive general discussion.</p> <p>The Private CEO Forum is only open to pre-series A private biotechs and spinouts of our TTO partners. This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge.</p> <p>Co-Hosts:</p> <p></p> <p>Timings:</p> <p>Feb 4, 16:00 - 17.45 - Synergy 2</p> <p>Case Study Roundtable</p> <p>Moderated discussion: How to approach and build relationships with VCs</p> <p>Nicholas Ibery, <i>Member of the Investment Committee, NCL Technology Venture</i> Claire Brown, <i>Investment Director, BioCity</i></p> <p>Term Sheet Workshop: Key VC terms and all you need to know on a term sheet.</p> <p><i>James Baillieu</i>, <i>Partner, Bird & Bird</i></p>	<p>M&A WORKSHOP</p> <p>Timings:</p> <p>Feb 5, 11:00 - 12.30 - Synergy 2</p> <p>This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge. Additional seats may be available on first-come first-served basis.</p> <p>Co-Hosts:</p> <p></p>	<p>CLINICAL STRATEGIES WORKSHOP</p> <p>Timings:</p> <p>Feb 5, 11:00 - 12.30 - Integrate 3</p> <p>This is a pre-registered session. If your seat is confirmed to attend, it is noted on your badge. Additional seats may be available on first-come first-served basis.</p> <p>Co-Hosts:</p> <p></p>
---	--	---	---	---

Showcase Profiles



Presenter: Catherine Schreiber, Dep. CEO

Market/Indication:

World's first method for the combined multi-organ support of liver, lung, kidney, and acid-base balance.

Funding Stage: Early Growth, Growth

Development Stage: On the Market, Clinical

Location: Germany

Track: Inv€\$table Medtech

Day and Time: Day 1, 17.00



Presenter: Michel Finance, CEO

Market/Indication:

Affluent Medical focuses on breakthrough therapies with a new approach of medical devices.

Funding Stage: Late Growth

Development Stage: Clinical

Location: France

Track: Inv€\$table Medtech

Day and Time: Day 1, 12.00



Presenter: Egill Masson, CEO

Market/Indication:

Development of therapeutics which enhance and deploy the body's own innate microbial defence mechanisms to combat debilitating infectious diseases.

Funding Stage: Seed

Development Stage: Drug Discovery, Pre-Clinical

Location: Iceland

Track: Inv€\$table Biotech

Day and Time: Day 1, 11.00



Presenter: Claudia Jimenez, General Manager

Market/Indication:

Proprietary and patent protected technologies to boost the production of recombinant proteins using Baculovirus vector expression systems (BVES) in insect cells.

Funding Stage: Growth

Development Stage: Filing / Reg. Approval

Location: Spain

Track: Inv€\$table Biotech

Day and Time: Day 1, 12.00



Presenter: David Mazzo, CEO

Market/Indication:

Late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies

Funding Stage: Publicly Listed

Ticker: NASDAQ:CLBS

Development Stage: Phase II

Location: United States

Track: Inv€\$table Biotech

Day and Time: Day 2, 12.30



Presenter: Ajan Reginald, CEO

Market/Indication:

Devoted to discovering breakthrough medicines that change the standard of medical care for patients.

Funding Stage: Private

Development Stage: Phase II

Location: United Kingdom

Track: Cardio Metabolic

Day and Time: Day 1, 14.15



Presenter: Gaudenz von Capeller, CFO

Market/Indication:

Pritavely-owned Biopharma - patented small molecule drug with an innovative mode of action targeting NOTCH-driven cancers, and providing hope for patients with no other treatment options.

Funding Stage: Early Growth

Development Stage: Phase I

Location: Switzerland

Track: Inv€\$table Biotech

Day and Time: Day 1, 17.15



Presenter: Celia Belline, CEO

Market/Indication:

To accelerate the development of novel therapies to prevent and treat hearing loss, tinnitus, and otitis

Funding Stage: Growth, Private

Development Stage: Pre-Clinical, Phase I, Phase II

Location: France

Track: Inv€\$table Biotech

Day and Time: Day 1, 16.30



Presenter: Myles Greenberg, President & CEO

Market/Indication:

Transforming the way vascular disease is treated, naturally, with Natural Vascular Scaffolding™ (NVS).

Funding Stage: Early Growth

Development Stage: Clinical, In Development

Location: United States

Track: Inv€\$table Medtech

Day and Time: Day 1, 13.45



Presenter: Yochi Slonim, Co-Founder & CEO

Market/Indication:

Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that control mRNA translation.

Funding Stage: Early Growth

Development Stage: Pre-Clinical

Location: United States

Track: Inv€\$table Biotech

Day and Time: Day 1, 16.15



Presenter: Andy Yates, CSO

Market/Indication:

Endocannabinoid system modulation - oncology and cancer associated anorexia, IBD, rare diseases

Funding Stage: Publicly Listed

Ticker: NASDAQ: ARTL

Development Stage: Phase II

Location: United States

Track: Inv€\$table Biotech

Day and Time: Day 1, 15.15



Presenter: Michael Malkoch, CEO

Market/Indication:

The most innovative fixation technology of bone fractures resulting in higher surgical success rate, faster recovery time and less pain suffering.

Funding Stage: Seed, Early Growth

Development Stage: Clinical, In Development

Location: Sweden

Track: Inv€\$table Medtech

Day and Time: Day 1, 15.00



Presenter: Jon H.Hoem, CEO & Co-Founder

Market/Indication:

The first medical device to diagnose and be a treatment platform for microvascular obstruction in heart attack patients

Funding Stage: Early Growth

Development Stage: Phase I

Location: Switzerland

Track: Inv€\$table Medtech

Day and Time: Day 1. 16.00



Presenter: Cristianne Rijcken, Founder & CSO

Market/Indication:

Targeted nanomedicines with superior therapeutic profiles for the treatment of cancer

Funding Stage: Growth, Private

Development Stage: Phase II

Location: Netherlands

Track: Licensable Biotech

Day and Time: Day 1, 11.30



Presenter: Neil Clark, CEO

Market/Indication:

Anti-infectives that prevent infection and improve outcomes for patients

Funding Stage: Publicly Listed

Ticker: LON: DEST

Development Stage: Drug Discovery, Phase II

Location: United Kingdom

Track: Inv€\$table Biotech

Day and Time: Day 1, 14.15



Presenter: Ulf Hannelius, President & CEO

Market/Indication:

Develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the exclusively in-licensed GAD molecule.

Funding Stage: Publicly Listed

Ticker: FRA:DMN

Development Stage: Phase I, Phase II

Location: Sweden

Track: Inv€\$table Biotech

Day and Time: Day 1, 14.30



Presenter: Pascal Neuville, CEO

Market/Indication:
Transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of CNS diseases and cancer.

Funding Stage: Early Growth, Private
Development Stage: Drug Discovery, Pre-Clinical, Phase I, Phase II
Location: France

Track: Inv€\$table Biotech
Day and Time: Day 2, 11.15




Presenter: Philip Huxley, CEO

Market/Indication:
Pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease.

Funding Stage: Seed
Development Stage: Pre-Clinical
Location: United Kingdom

Track: Licensable Biotech
Day and Time: Day 1, 11:15



Presenter: Shlomi Raz, CEO

Market/Indication:
Dedicated to unlocking the therapeutic potential of serotonin 2A receptor agonists, commonly referred to as psychedelics, through the mitigation and management of psychoactivity

Funding Stage: Early Growth
Development Stage: Drug Discovery, Pre-Clinical, Phase I, Phase II
Location: United Kingdom

Track: Inv€\$table Biotech
Day and Time: Day 1, 12.15



Presenter: Juho Jalkanen, CDO

Market/Indication:
Clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs.

Funding Stage: Growth
Development Stage: Phase II
Location: Finland

Track: Licensable Biotech
Day and Time: Day 1. 11.00



Presenter: Pete O'Heeron , CEO

Market/Indication:
Regenerative medicine company developing an innovative regenerative medicine solution for chronic diseases using fibroblasts.

Funding Stage: Early Growth, Private
Development Stage: Phase II
Location: United States

Track: Licensable Biotech
Day and Time: Day 1, 11.45



Presenter: Jan Alenfall, CEO

Market/Indication:
Our research and development is currently focused on the stimulation of hair growth and diabetes.

Funding Stage: Early Growth
Development Stage: Drug Discovery, Phase II
Location: Sweden

Track: Cardio Metabolic
Day and Time: Day 1, 15:15



Presenter: Michael Pehl, CEO

Market/Indication:
Discover, develop, manufacture and commercialize next generation immunotherapies for the treatment of cancer patients

Funding Stage: Seed, Private
Development Stage: Pre-Clinical, Phase I
Location: Germany

Track: Inv€\$table Biotech
Day and Time: Day 2, 11.30



Presenter: Lorenzo Pradella, CEO

Market/Indication:
GreenBone is a leading bone regeneration company founded in 2014 addressing high unmet medical needs in the field of orthopaedics and bone diseases.

Funding Stage: Growth
Development Stage: Filing / Reg. Approval, Clinical
Location: Italy

Track: Inv€\$table Medtech
Day and Time: Day 1. 11.00



Presenter: Adam Robertson, CSO

Market/Indication:
Developing pharmaceuticals to treat glioblastoma multiforme patients. Hemispherian scientists have identified and are advancing compounds that are highly effective in treating these tumors.

Funding Stage: Seed
Development Stage: Drug Discovery, Pre-Clinical
Location: Norway

Track: Inv€\$table Biotech
Day and Time: Day 1, 11.30



Presenter: Sijme Zeilemaker, COO

Market/Indication:
Novel immuno-oncology approach to treat solid tumours through its lead program Ilixadencel.

Funding Stage: Publicly Listed
Ticker: STO: IMMU
Development Stage: Phase II
Location: Sweden

Track: Inv€\$table Biotech
Day and Time: Day 1, 14.00



Presenter: Orest Lastow, CEO

Market/Indication:
ICONOVO is a Swedish privately funded device company with a business model to supply the market with unique, safe and cost efficient inhalation devices.

Funding Stage: Growth
Development Stage: Filing / Reg. Approval, Clinical, In Development
Location: Sweden

Track: Inv€\$table Medtech
Day and Time: Day 1, 12.15



Presenter: Grace E. Colón, President & CEO

Market/Indication:
Novel approach of treating cardiovascular conditions by the inhalation route.

Funding Stage: Early Growth, Private
Development Stage: Phase II
Location: United States

Track: Inv€\$table Biotech
Day and Time: Day 2, 12.00



Presenter: Andrew Woodland, CSO

Market/Indication:
We are discovering the next generation of therapies for skin diseases, including eczema, non-melanoma skin cancers and orphan skin diseases.

Funding Stage: Seed
Development Stage: Drug Discovery
Location: United Kingdom

Track: Inv€\$table Biotech
Day and Time: Day 1, 17.30



Presenter: Richard Boyd, CEO

Market/Indication:
Improving outcomes for patients on dialysis, and other extra-corporeal treatments

Funding Stage: Early Growth
Development Stage: Pre-Clinical
Location: United Kingdom

Track: Inv€\$table Medtech
Day and Time: Day 1, 12.30



Presenter: David Tuch, CEO

Market/Indication:
The company develops and markets molecular imaging and sensing technologies to enable surgeons to detect cancer in real time during surgery and improve health outcomes for cancer patients.

Funding Stage: Growth
Development Stage: Clinical
Location: United Kingdom

Track: Inv€\$table Medtech
Day and Time: Day 1. 15.45



Presenter: Veronica Gambillara Fonck, CEO

Market/Indication:
Translating novel scientific concepts into early proof of concepts for both the prevention and treatment of life-threatening diseases.

Funding Stage: Seed
Development Stage: Drug Discovery
Location: Switzerland

Track: Inv€\$table Biotech
Day and Time: Day 1, 16.00



Presenter: Oren Glanz, CEO

Market/Indication:

We are a pre-clinical biotech company, pioneering a paradigm shift in the modification of the innate immune system to effectively combat severe diseases.

Funding Stage: Seed

Development Stage: Drug Discovery, Pre-Clinical
Location: Israel

Track: Cardio Metabolic
Day and Time: Day 1, 14.30



Presenter: Leonie De Best, CBO

Market/Indication:

Pre-clinical stage biotech company, developing novel antibiotics, so called Synthetic Anti-Microbial and Anti-Biofilm Peptides (SAAPs) to combat a wide variety of (resistant) bacterial infections.

Funding Stage: Seed

Development Stage: Pre-Clinical
Location: Netherlands

Track: Inv€\$table Biotech 2
Day and Time: Day 1, 16:15



Presenter: John Burt, CEO

Market/Indication:

Medherant has built upon its founders' world-leading expertise in bio-adhesives and polymer chemistry to create its unique patent protected TEPI Patch® drug delivery technology.

Funding Stage: Early Growth

Development Stage: Pre-Clinical
Location: United Kingdom

Track: Inv€\$table Medtech
Day and Time: Day 1, 11.30



Presenter: Christina Herder, EVP, COO

Market/Indication:

Medivir is a drug discovery and development company focusing on transformative cancer drugs.

Funding Stage: Publicly Listed

Ticker: STO: MVIR-B
Development Stage: Phase I, Phase II
Location: Sweden

Track: Inv€\$table Biotech
Day and Time: Day 1, 15.00



Presenter: Natalia Perekhvatova, CEO

Market/Indication:

Rapid development of break-through pharmaceutical products based on mitochondria targeted antioxidants.

Funding Stage: Growth

Development Stage: Phase III
Location: Luxembourg

Track: Cardio Metabolic
Day and Time: Day 1, 14.00



Presenter: Brian Shields, CEO

Market/Indication:

Minimally invasive hand-held radio-frequency device which ENT surgeons will use to treat patients in an office setting, removing the complications and costs associated with most surgical procedures.

Funding Stage: Early Growth

Development Stage: Clinical,
Location: Ireland

Track: Inv€\$table Medtech
Day and Time: Day 1, 16.15



Presenter: Lorenzo Rossi, CEO

Market/Indication:

Newronika builds innovative brain devices based on its large knowledge on biosignal decoding

Funding Stage: Early Growth

Development Stage: Filing / Reg. Approval, Clinical
Location: Italy

Track: Inv€\$table Medtech
Day and Time: Day 1, 15.15



Presenter: Ewen Northwood, Director

Market/Indication:

NirVisio is developing and will commercialise a family of Near Infra-Red (NIR) imaging devices that will transform dental healthcare by improving the detection and monitoring of dental caries

Funding Stage: Pre-Seed

Development Stage: Pre-Clinical
Location: United Kingdom

Track: Inv€\$table Biotech
Day and Time: Day 2, 11.45



Presenter: Begüm Utz, Product Manager

Market/Indication:

Improving the diagnosis, treatment and prevention of acute neurodegenerative conditions and is currently focused on developing a diagnostic kit for the detection of Traumatic Brain Injury.

Funding Stage: Early Growth

Development Stage: Phase II
Location: Finland

Track: Inv€\$table Medtech
Day and Time: Day 1, 16.45



Presenter: Konstantin Chernov, CEO

Market/Indication:

We investigate transport- and binding functions of albumin in the blood with the aim to improve the diagnostic of life-threatening diseases

Funding Stage: Early Growth, Private

Development Stage: Pre-Clinical, Filing / Reg. Approval, On the Market, Clinical, In Development
Location: Germany

Track: Inv€\$table Medtech
Day and Time: Day 1, 17.30



Presenter: Barry Sharples, Chairman

Market/Indication:

Focused out of the public eye for 7 years, developing what we believe to be a paradigm shift in stem cell science.

Funding Stage: Growth, Private

Development Stage: Pre-Clinical, Phase I/II
Location: United Kingdom

Track, Day and Time: Inv€\$table Biotech, Day 1, 11.15, Cardio Metabolic, Day 1, 15.00



Presenter: Mike Romanos, CEO

Market/Indication:

Microbiotica has programs in IBD, immune-oncology and Clostridium difficile, developing medicines and biomarkers based on microbiota.

Funding Stage: Early Growth

Development Stage: Drug Discovery, Pre-Clinical
Location: United Kingdom

Track: Inv€\$table Biotech
Day and Time: Day 1, 14.45



Presenter: Denis Dufrane, CSO / Co-Founder

Market/Indication:

Novadip has developed a unique tissue regeneration platform capable of generating multiple product classes to transform the lives of patients with limited or no effective treatment options.

Funding Stage: Private

Development Stage: Phase II
Location: Belgium

Track: Inv€\$table Biotech
Day and Time: Day 2, 11.00



Presenter: David Urech, CEO

Market/Indication:

Offering cutting-edge discovery of ready-to-develop multispecific biotherapeutics to partners.

Funding Stage: Growth

Development Stage: Drug Discovery, Pre-Clinical, Phase I
Location: Switzerland

Track: Inv€\$table Biotech 2
Day and Time: Day 1, 16:30



Presenter: Hanno Markshied, CEO

Market/Indication:

Innovative sealants and surgical patches based on unique combinations of advanced bioactive materials and optimized, electrospun nanofiber matrices.

Funding Stage: Early Growth

Development Stage: Clinical
Location: Israel

Track: Inv€\$table Medtech
Day and Time: Day 1, 11.15



Presenter: Martin Olovsson, CEO

Market/Indication:

The OnDosis device offers a new way to deliver prescription treatment: integrating medicine with intelligent dosing.

Funding Stage: Seed, Early Growth

Development Stage: Filing, Reg. Approval, In Development
Location: Sweden

Track: Inv€\$table Medtech
Day and Time: Day 1, 14.30



Presenter: Carlos Buesa, CEO

Market/Indication:
Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.

Funding Stage: Publicly Listed
Development Stage: Phase II
Ticker: BME: ORY
Location: Spain

Track: Inv€\$table Biotech
Day and Time: Day 1, 15.30



Presenter: Yoav Lichtenstein, CEO

Market/Indication:
State-of-the-art innovative practical GI endoscopy solutions, Versatile, on-demand, easy-to-assemble, cost-effective, colonoscopy assist device.

Funding Stage: Seed
Development Stage: In development
Location: Israel

Track: Inv€\$table Medtech
Day and Time: Day 1, 16.30



Presenter: Stuart Collinson, CEO

Market/Indication:
OxStem is developing small molecule therapeutics targeting innate regeneration and repair.

Funding Stage: Early Growth
Development Stage: Drug Discovery
Location: United Kingdom

Track: Cardio Metabolic
Day and Time: Day 1, 14.45



Presenter: Julian Howell, Co-Founder & CEO

Market/Indication:
We are an early-stage research and development company — our mission is to save kidneys and prevent pain in people with Cystinuria.

Funding Stage: Seed
Development Stage: Pre-Clinical
Location: United Kingdom

Track: Inv€\$table Biotech
Day and Time: Day 2, 12.15



Presenter: Nawal Ouzren, CEO

Market/Indication:
Biopharmaceutical company developing life-transforming therapies for patients with inner ear disorders involving vertigo and hearing loss.

Funding Stage: Publicly Listed
Ticker: ENX:ALSEN
Development Stage: Pre-Clinical, Phase II
Location: France

Track: Inv€\$table Biotech 2
Day and Time: Day 1, 16.00



Presenter: Suzanne Saffie-Siebert, CEO

Market/Indication:
ProSilic® is our bio-courier engineered to maximise the therapeutic benefits of drug molecules and active ingredients.

Funding Stage: Growth
Development Stage: Pre-Clinical
Location: United Kingdom

Track: Inv€\$table Biotech
Day and Time: Day 1, 17.00



Presenter: Jack Lee, CEO

Market/Indication:
Ring-type Cardio Tracker, CART to help continuous monitoring of atrial fibrillation which is difficult to diagnose even in a hospital in daily life.

Funding Stage: Early Growth
Development Stage: Phase III, Filing / Reg. Approval
Location: South Korea

Track: Inv€\$table Medtech
Day and Time: Day 1, 14:45



Presenter: Halvor Celius, CEO

Market/Indication:
SonoClear is developing a product for enhanced ultrasound image quality in brain tumor surgery, providing the neurosurgeon with a powerful tool to achieve complete tumor removal.

Funding Stage: Seed / Private
Development Stage: In Development
Location: Norway

Track: Inv€\$table Medtech
Day and Time: Day 1, 15.30



Presenter: Ivo Timmermans, CEO

Market/Indication:
Dutch private limited company, established to develop a portfolio of therapies in the field of cancer medicine.

Funding Stage: Seed
Development Stage: Pre-Clinical
Location: Netherlands

Track: Inv€\$table Biotech
Day and Time: Day 1, 15.45



Presenter: Lone Veng, CEO

Market/Indication:
Focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin A1 as resolution therapy

Funding Stage: Early Growth
Development Stage: Drug Discovery, Pre-Clinical
Location: Denmark

Track: Cardio Metabolic
Day and Time: Day 1, 15.45



Presenter: Mark Rushworth, MD

Market/Indication:
SageTech has developed a comprehensive way to capture, extract and purify volatile anaesthetic gases to PhEur monograph standard.

Funding Stage: Seed
Development Stage: Filing / Reg. Approval, Clinical
Location: United Kingdom

Track: Inv€\$table Medtech
Day and Time: Day 1, 14.00



Presenter: Cliff Holloway, CEO

Market/Indication:
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body's own immune system.

Funding Stage: Publicly Listed
Ticker: LON: SCLP
Development Stage: Pre-Clinical, Phase I, Phase II
Location: United Kingdom

Track: Inv€\$table Biotech
Day and Time: Day 1, 16.45



Presenter: Andrew Parker, CEO

Market/Indication:
Step Pharma is a biotechnology company discovering and developing proprietary small molecule therapeutics for the treatment of auto-immune diseases.

Funding Stage: Early Growth
Development Stage: Pre-Clinical
Location: France

Track: Inv€\$table Biotech
Day and Time: Day 1, 11.15



Presenter: Attila Borbath, CEO

Market/Indication:
We are pioneering optoelectronics for neurostimulation medical devices by developing innovations to provide a powerful and versatile neurostimulation technological platform.

Funding Stage: Growth
Development Stage: Pre-Clinical
Location: Belgium

Track: Inv€\$table Medtech
Day and Time: Day 1, 11:45



Presenter: Nikolaos Deliolanis, CEO

Market/Indication:
Thericon is the first to bring multiparametric imaging to the operating theater. This allows for displaying of previously invisible tissue properties together with standard color images on a single screen.

Funding Stage: Seed, Private
Development Stage: Clinical, In Development
Location: Germany

Track: Inv€\$table Medtech
Day and Time: Day 1, 17.15



Presenter: David Yudovich, CEO

Market/Indication:
Full scope gene editing analysis solution that combines proprietary sequencing algorithms together with cost-effective, immediate access, and rapid turnaround sample processing services.

Funding Stage: Seed
Development Stage: Pre-Clinical, On the Market, In Development
Location: Sweden

Track: Inv€\$table Biotech
Day and Time: Day 1, 12.30



Presenter: Michael Stein, CEO

Market/Indication:

Immuno-oncology company developing novel, rapidly adaptable therapeutic cancer immunotherapies using its patented PeptiCRAd and PeptiENV platforms.

Funding Stage: Early Growth
Development Stage: Pre-Clinical
Location: Finland

Track: Inv€\$table Biotech
Day and Time: Day 1, 16.45



Verona Pharma

Presenter: Piers Morgan, CFO

Market/Indication:

Focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases.

Funding Stage: Publicly Listed
Ticker: AIM:VRP
Development Stage: Phase II
Location: United Kingdom

Track: Inv€\$table Biotech
Day and Time: Day 1, 13.45



Presenter: Vincent Forster, CEO

Market/Indication:

Versantis develops a new generation of liver disease therapeutics and diagnostics.

Funding Stage: Growth
Development Stage: Phase I
Location: Switzerland

Track: Cardio Metabolic
Day and Time: Day 1, 15.30



Presenter: Eliane Schutte, CEO

Market/Indication:

Xeltis is a clinical-stage medical device company pioneering a restorative approach in cardiovascular therapy.

Funding Stage: Growth
Development Stage: Clinical
Location: Netherlands / Switzerland

Track: Inv€\$table Medtech
Day and Time: Day 1, 14:15



HOSTED BY:



The Digital Poster Innovation Zone hosted by MSD runs across both days and is an opportunity to connect with and explore the next generation of bio and medical technologies being developed by entrepreneurs from across Europe's leading TTOs. Digital posters can be viewed at any time throughout the conference.

Discover the life science executive leaders of tomorrow!

ALCEDIAG
ALCEN



DIOGEN



MorphGI



Onsite Networking Opportunities

Networking Party



What's an event without some fun? The World Congress networking party on the evening of day one is the perfect opportunity to unwind, let your hair down and informally network with the community.

Relax, network and make unexpected connections over a drink (or few!).

HOSTED BY:



Investor Dinner



If you have purchased a ticket to the Investor-only dinner, you will be directed from the conference venue at approx. 7pm to the dinner venue for a gourmet 3-course networking dinner. Your badge will confirm you have a seat reserved. This dinner required pre-registration and is a sell out.

1:1 Partnering



Maximise your out-of-session networking time and secure those vital face-to-face meetings. The partnering system went live with your profile filled in from the information provided on registration and allows you to search for potential partners and book meetings in the extensive 1-2-1 partnering area.

HOSTED BY:



Industry Leading Events for the Life Science C-suite



21-22 April 2020, etc. venues, 133 Houndsditch, London, UK
www.longevityleaders.com



2-3 September 2020, Nasdaq Offices, Stockholm, Sweden
www.lsxleaders.com/nordic



16 November 2020, Old Billingsgate, London, UK
www.lsxleaders.com/investival



16-17 November 2020, Old Billingsgate, London, UK
www.lsxleaders.com/digihealth



17 November 2020, The Honourable Artillery Company, London, UK
www.lsxleaders.com/lifestars



2-3 February 2021, etc. venues, 133 Houndsditch, London, UK
www.lsxleaders.com/world

Congress & Exhibition Floorplan

